Schering AG/Epix' Imaging Agent Requires Additional Clinical Studies, FDA Says

FDA requests further clinical studies for MS-325 (gadofosveset trisodium) to demonstrate efficacy, the "approvable" letter states. The outstanding questions relate to the non-contrast comparator scanning methods used in Phase III trials and the statistical treatment of uninterpretable baseline scans.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet